Literature DB >> 19812054

Adjusting for clinical covariates improves the ability of B-type natriuretic peptide to distinguish cardiac from non-cardiac dyspnoea: a sub-study of HEARD-IT.

R Kevin Rogers1, Josef Stehlik, Gregory J Stoddard, Thomas Greene, Sean P Collins, W Frank Peacock, Alan D Maisel, Paul Clopton, Andrew D Michaels.   

Abstract

AIMS: We sought to create a model that adjusts B-type natriuretic peptide (BNP) for specific covariates to better distinguish cardiac from non-cardiac dyspnoea. METHODS AND
RESULTS: HEARD-IT was a multicentre, prospective study of the diagnostic utility of acoustic cardiography in the emergency department. Dyspnoeic patients more than 40 years were eligible. Two cardiologists independently adjudicated the HF outcome. Using logistic regression, a model adjusting BNP for pertinent covariates was developed (n = 740). The mean age was 66 +/- 13 years. Age, gender, ethnicity, body mass index, blood urea nitrogen, and creatinine affected BNP levels independently of HF. The model adjusting BNP for these covariates improved the area under receiver operator characteristic curve for HF compared with BNP alone (0.948, 95% CI 0.934-0.963 vs. 0.937, 95% CI 0.920-0.954; P = 0.004). Net reclassification improvement, a novel metric of model performance, was 3.5% for those without HF (P = 0.05) compared with conventional, unadjusted BNP cut-offs. Thirteen of 116 (11%) patients without HF, but with unadjusted BNP values > or =100 pg/mL, were correctly reclassified as not having HF with the adjusted BNP model.
CONCLUSION: Adjusting BNP for important covariates may improve its ability to distinguish cardiac from non-cardiac dyspnoea.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19812054     DOI: 10.1093/eurjhf/hfp127

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  5 in total

Review 1.  Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence.

Authors:  Stephen A Hill; Ronald A Booth; P Lina Santaguida; Andrew Don-Wauchope; Judy A Brown; Mark Oremus; Usman Ali; Amy Bustamam; Nazmul Sohel; Robert McKelvie; Cynthia Balion; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

2.  Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy.

Authors:  Achal Gupta; Eugene Braunwald; Steven McNulty; G Michael Felker; E Michael Gilbert; Rami Alharethi; Kerry L Lee; Kevin J Anstrom; Margaret M Redfield; Steven R Goldsmith; Christopher M O'Connor; David A Bull; Josef Stehlik; Sheldon E Litwin
Journal:  J Card Fail       Date:  2012-11       Impact factor: 5.712

3.  Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial.

Authors:  Alan S Maisel; Christian Mueller; Robert Fitzgerald; Robert Brikhan; Brian C Hiestand; Navaid Iqbal; Paul Clopton; Dirk J van Veldhuisen
Journal:  Eur J Heart Fail       Date:  2011-08       Impact factor: 15.534

Review 4.  The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting.

Authors:  Emmert Roberts; Andrew J Ludman; Katharina Dworzynski; Abdallah Al-Mohammad; Martin R Cowie; John J V McMurray; Jonathan Mant
Journal:  BMJ       Date:  2015-03-04

5.  Quantifying how diagnostic test accuracy depends on threshold in a meta-analysis.

Authors:  Hayley E Jones; Constantine A Gatsonsis; Thomas A Trikalinos; Nicky J Welton; A E Ades
Journal:  Stat Med       Date:  2019-09-30       Impact factor: 2.373

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.